Skip to main content

Table 2 Baseline characteristics of included studies

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Authors (Year) Materials Detection Antibody Dilution Positive site Cut-off value Estimates Extractions Analysis Endpoints Follow-up
Boone et al. (2008) [38] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 20 % staining OR DDE U –––– ––––
Chen et al. (2010) [39] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 Cytoplasm 10 % staining OR DDE U –––– ––––
Chuang et al. (2015) [40] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 NI Median H-score OR, HR DDE U OS 120 months
Hirashima et al. (2010) [41] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining OR, HR Reported, DDE U & M OS, CSS 133 months
Hou et al. (2014) [42] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:200 Cytoplasm 10 % staining OR DDE U –––– ––––
Kim et al. (2013) [43] Paraffin-embedded tissue IHC Ser2448 1:100 NI 5 % staining OR, HR Reported, DDE U & M OS, CSS 120 months
Li et al. (2012) [44] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining HR Reported M OS, DFS 120 months
Li et al. (2015) [45] Paraffin-embedded tissue IHC Ser2448 1:50 Cytoplasm 10 % staining OR, HR DDE U OS, DFS 146 months
Lu et al. (2015) [46] Paraffin-embedded tissue IHC Rabbit anti-mTOR 1:100 Cytoplasm 25 % staining OR, HR Reported, DDE U & M OS, DFS 36 months
  1. CP clinicopathological, CSS cancer-specific survival, DDE demographic data extrapolated, DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, M multivariate, NE negative expression, NI no information, NIT neo-adjuvant induction therapy, NOS Newcastle-Ottawa Scale, OR odds ratio, OS overall survival, PE positive expression, ROS retrospective observational study, U univariate